The estimated Net Worth of Elizabeth Crowley is at least $2.17 Milion dollars as of 14 June 2024. Ms. Crowley owns over 30,000 units of Celldex Therapeutics stock worth over $1,627,041 and over the last 7 years she sold CLDX stock worth over $0. In addition, she makes $547,654 as Senior Vice President i Chief Product Development Officer at Celldex Therapeutics.
Elizabeth has made over 5 trades of the Celldex Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 30,000 units of CLDX stock worth $311,400 on 14 June 2024.
The largest trade she's ever made was exercising 42,945 units of Celldex Therapeutics stock on 30 May 2024 worth over $172,209. On average, Elizabeth trades about 7,731 units every 74 days since 2017. As of 14 June 2024 she still owns at least 39,074 units of Celldex Therapeutics stock.
You can see the complete history of Ms. Crowley stock trades at the bottom of the page.
Elizabeth Crowley serves as Senior Vice President, Chief Product Development Officer of the Company. Ms. Crowley served as Senior Vice President, Product Development of Celldex from July 2014 to August 2016. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management. Ms. Crowley received her B.S. in Chemistry with a concentration in Business from Boston College.
As the Senior Vice President i Chief Product Development Officer of Celldex Therapeutics, the total compensation of Elizabeth Crowley at Celldex Therapeutics is $547,654. There are 10 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
Elizabeth Crowley is 48, she's been the Senior Vice President i Chief Product Development Officer of Celldex Therapeutics since 2016. There are 22 older and 2 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Elizabeth's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil oraz Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: